Check 35,000+ stocks against 26 valuation models and 37 quality factors

Hang Fat Ginseng Holdings Co (0911) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of Hang Fat Ginseng Holdings Co HK$0.89, price HK$0.38, upside +134.2%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG7307F1046

HF Thin data Sep 27, 2026

Hang Fat Ginseng Holdings Co

0911 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value HK$0.8900 · Strongly undervalued (+134.2%)

✓Quality 69/100

!Weak Growth (revenue 5y −2.3 %/yr)

!Thin margins · 0.9% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (9/13)

!Narrow moat 16/100

!Evidence only low, so the estimate is less certain

!Weak on past: 6 out of 100

26 models, one by oneBear HK$0.6300 to bull HK$1.16 Growth analysisrevenue history, year by year Quality 69/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Hang Fat Ginseng Holdings Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.0230 – HK$1.20 · fair‑value band HK$0.6300 – HK$1.16 · the HK$0.3800 price screens below the HK$0.8900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 27, 2026.

Follow Hang Fat Ginseng Holdings Co in your weekly email

Every Wednesday you see whether Hang Fat Ginseng Holdings Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Qianhai Health Holdings Limited, an investment holding company, engages in the trading and sale of electronic components, and health-care products and food businesses in Hong Kong. It offers Chinese herbal medicines and other health care products; and administrative services. The company also sells health beverages, ginseng wine, and skin-care products. In addition, it is involved in the sale of information technology component products, including NAND flash wafer, a thin slice of semiconductor material, such as silicon, a component of flash memory integrated circuits; and embed multi-chip package memory, an electronic component containing several memory chip and other electronic components. The company was formerly known as Hang Fat Ginseng Holdings Company Limited and changed its name to Qianhai Health Holdings Limited in September 2016. Qianhai Health Holdings Limited was founded in 1989 and is based in Sheung Wan, Hong Kong. Qianhai Health Holdings Limited is a subsidiary of Explorer Rosy Limited.

Stock analysis

Hang Fat Ginseng Holdings Co (0911) currently trades at HK$0.3800, while our model-based Fair Value estimate is HK$0.8900, implying the stock looks roughly 57.3% undervalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of HK$2.47 per share, and 24 of the 24 models we run sit above the HK$0.3800 price.

Bear case: the Earnings-Based group reads lowest at HK$0.6100, and 0 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$0.6300 (bear) to HK$1.16 (bull), the price of HK$0.3800 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Hang Fat Ginseng Holdings Co reported revenue of HK$677M in FY2025 versus HK$283M in FY2021, a compound +24.3%/yr. Reported net income was HK$5.9M in FY2025.

Key figures

Market cap HK$108M (≈ $13.8M) · P/E ratio 16.0 · P/S ratio 0.14 · EPS (TTM) HK$0.0300 · Net margin 0.9% · Return on equity 1.5% · Return on assets (EBIT) −7.4% · Operating margin 0.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 68% below its 52-week high and 49% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 134%, 0911 screens cheaper than that median.

Fair Value models

Bear HK$0.6300 Fair Value HK$0.8900 Bull HK$1.16

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0224 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

5Y EBITDA Exit HK$1.59 HK$2.16 HK$2.84 74

EPV HK$0.6400 HK$0.6800 HK$0.7200 74

FCF DCF HK$3.56 HK$5.97 HK$12.10 73

All 24 models by family

DCF Models

FCF DCF HK$3.56 HK$5.97 HK$12.10 73

Owner Earnings HK$0.9800 HK$1.63 HK$2.89 71

5Y Revenue Exit HK$1.56 HK$2.07 HK$2.73 71

5Y EBITDA Exit HK$1.59 HK$2.16 HK$2.84 74

5Y P/E Exit HK$1.72 HK$2.47 HK$3.31 69

10Y Revenue Exit HK$2.17 HK$2.97 HK$4.00 65

10Y EBITDA Exit HK$2.21 HK$3.04 HK$4.23 67

10Y P/E Exit HK$2.30 HK$3.26 HK$4.65 62

Earnings-Based

Graham-Dodd HK$0.2400 HK$1.49 HK$2.08 61

Lynch FV HK$0.4300 HK$0.6100 HK$0.7900 59

PEG = 1.0 HK$0.4300 HK$0.6100 HK$0.7900 55

EPV HK$0.6400 HK$0.6800 HK$0.7200 74

Multiples

P/E Multiple HK$0.5800 HK$0.7700 HK$0.9600 63

P/S Multiple HK$0.4500 HK$0.6000 HK$0.7500 58

P/B Multiple HK$0.4500 HK$0.6000 HK$0.7500 55

EV/EBIT HK$0.8100 HK$0.9600 HK$1.11 66

EV/EBITDA HK$0.7400 HK$0.8700 HK$1.00 67

EV/Revenue HK$0.6700 HK$0.8000 HK$0.9300 54

Asset-Based

NCAV (Graham) HK$1.15 HK$1.55 HK$2.31 54

Growth DCF

Growth DCF HK$3.45 HK$6.51 HK$11.48 73

Rev-Margin DCF HK$1.56 HK$2.11 HK$2.89 71

Economic Profit

Residual Income HK$1.58 HK$1.47 HK$1.43 68

ROIC Compounder HK$0.6400 HK$0.6800 HK$0.7200 70

Growth Earnings

Growth-Adj P/E HK$0.6300 HK$0.8900 HK$1.16 65

Open the full fair value analysis →

Notify me when 0911 reaches fair value

Put 0911 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 69/100

Of which business quality 70 · Market factors (momentum, volatility) 42

Profitability 34

Margins and returns on capital today

Quality Growth 64

Are margins and returns improving?

Cashflow 67

Earnings quality: real cash, not paper profit

Fin. Strength 90

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 10

Calm price path (market factor)

Momentum 63

Price trend over the last 3–12 months (market factor)

52W Momentum 43

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 39/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+30.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−29.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−2.3%

Start year 2020 (pandemic). Over 10 years: −2.1% a year

Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.0%

’12

’13

’14

’15

’16

’17

’19

’20

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−26.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year−26.0%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−26.0% vs −38.7%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 1%

Start year 2020 (pandemic)

⚠ Revenue per share shrinking 12.5%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Watch 0911, get fair value alerts →

Compare Hang Fat Ginseng Holdings Co with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 622 stocks

Beats the industry median on 8/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 69 · Top 25%

Fair Value upside +134.2% · Top 25%

Profitability

Return on equity (TTM) 1.5% · Below median

Return on assets 0.9% · Below median

Net margin (TTM) 0.9% · Below median

Operating margin (TTM) 0.3% · Below median

Growth and dividend

Revenue growth 58.1% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 16.0× · Cheaper than median

P/B 0.28× · Cheapest 25%

P/S (TTM) 0.16× · Cheapest 25%

P/FCF 2.8× · Cheapest 25%

EV/EBITDA 7.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 16

FUTURE (revenue growth)100 · sector 18

PAST (return on equity)6 · sector 26

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€135.00	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$71.05	$110.50	+56%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hang Fat Ginseng Holdings Co · Fair Value
HK$0.8900 +57%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0911" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Hang Fat Ginseng Holdings Co · Fair Value</span><br><b style="font-size:20px">HK$0.8900</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+57%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Hang Fat Ginseng Holdings Co Fair Value". https://www.fairvalue-calculator.com/stock/0911

Frequently asked questions

Is Hang Fat Ginseng Holdings Co (0911) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$0.8900 versus a price of HK$0.3800, about +134% upside (undervalued).

What is the fair value of 0911?

Our model-based fair value for Hang Fat Ginseng Holdings Co is HK$0.8900 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.3800.

What is the quality score of 0911?

Hang Fat Ginseng Holdings Co has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Hang Fat Ginseng Holdings Co (0911)?

Our model-based price target is the fair value of HK$0.8900 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$0.6300, optimistic scenario HK$1.16. It is a calculation from audited fundamentals, not an analyst target.

What is the Hang Fat Ginseng Holdings Co stock forecast for 2026?

Our models put fair value at HK$0.8900, about +134% upside versus a price of HK$0.3800 (undervalued). Cautious scenario HK$0.6300, optimistic scenario HK$1.16. The calculation is refreshed regularly with new filings.

What is the revenue of Hang Fat Ginseng Holdings Co (0911)?

Hang Fat Ginseng Holdings Co reported trailing-twelve-month revenue of about HK$677M (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Hang Fat Ginseng Holdings Co (0911)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hang Fat Ginseng Holdings Co it is HK$0.8900 per share (as of Sep 27, 2026), against a price of HK$0.3800. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Hang Fat Ginseng Holdings Co stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 0911 trades below its calculated fair value: price HK$0.3800, fair value HK$0.8900, a gap of about +134% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0911?

No. The price is what the market pays today (HK$0.3800); the fair value is what the company's own numbers justify (HK$0.8900). For Hang Fat Ginseng Holdings Co the two are HK$0.5100 per share apart. That gap is exactly why we show both numbers side by side.

How much is Hang Fat Ginseng Holdings Co worth?

The market values Hang Fat Ginseng Holdings Co at about HK$108M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.3800; our models calculate a fair value of HK$0.8900 per share.

What do the bullish and bearish scenarios say about 0911?

Our models span a range for Hang Fat Ginseng Holdings Co: cautious scenario HK$0.6300, base HK$0.8900, optimistic HK$1.16 per share (as of Sep 27, 2026, price HK$0.3800). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0911?

Hang Fat Ginseng Holdings Co trades at a price-to-earnings ratio of 16.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.8900 is built from several models across several years. Other multiples: P/B 0.3, P/S 0.2, EV/EBITDA 7.2.

How solid is the balance sheet of Hang Fat Ginseng Holdings Co (0911)?

Balance-sheet figures for Hang Fat Ginseng Holdings Co (as of Sep 27, 2026): return on equity 1.5%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.

How far is 0911 from its 52-week high?

Hang Fat Ginseng Holdings Co trades at HK$0.3800, about 68% below its 52-week high of HK$1.20 and 49% above the low of HK$0.2550 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.8900 is for.

Which stocks are comparable to Hang Fat Ginseng Holdings Co?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Hang Fat Ginseng Holdings Co stock attractive at the current price?

The data as of Sep 27, 2026: price HK$0.3800, calculated fair value HK$0.8900 (+134%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0911 calculated?

We run Hang Fat Ginseng Holdings Co through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.8900, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.9 % above its aggregate fair value. Hang Fat Ginseng Holdings Co currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Hang Fat Ginseng Holdings Co (0911)?

The closing price on Sep 29, 2026 was HK$0.3800. Our model-based fair value is HK$0.8900, about +134% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Hang Fat Ginseng Holdings Co right now?

The price is below even our cautious bear case (HK$0.6300). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$0.6300 to HK$1.16) leaves room in how you read the outcome.

Key figures of Hang Fat Ginseng Holdings Co

How large is the market capitalisation of Hang Fat Ginseng Holdings Co (0911)?

The market capitalisation of Hang Fat Ginseng Holdings Co is HK$108M (≈ $13.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Hang Fat Ginseng Holdings Co (0911)?

The price-to-sales ratio of Hang Fat Ginseng Holdings Co is 0.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Hang Fat Ginseng Holdings Co (0911)?

Earnings per share at Hang Fat Ginseng Holdings Co are HK$0.0300 (price ÷ EPS = P/E 16.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Hang Fat Ginseng Holdings Co (0911)?

The net margin of Hang Fat Ginseng Holdings Co is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Hang Fat Ginseng Holdings Co (0911)?

The return on equity (ROE) of Hang Fat Ginseng Holdings Co is 1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Hang Fat Ginseng Holdings Co (0911)?

On an EBIT basis the return on assets of Hang Fat Ginseng Holdings Co is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Hang Fat Ginseng Holdings Co (0911)?

The operating margin of Hang Fat Ginseng Holdings Co is 0.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Hang Fat Ginseng Holdings Co (0911)?

Revenue at Hang Fat Ginseng Holdings Co is growing +58.1% versus a year earlier (3y avg −29.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Hang Fat Ginseng Holdings Co (0911)?

Earnings per share at Hang Fat Ginseng Holdings Co are growing −69.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Hang Fat Ginseng Holdings Co (0911) generate?

The free cash flow of Hang Fat Ginseng Holdings Co is HK$38.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Hang Fat Ginseng Holdings Co (0911) hold?

Hang Fat Ginseng Holdings Co holds more cash than debt, HK$61.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Hang Fat Ginseng Holdings Co in the live analysis

One click puts Hang Fat Ginseng Holdings Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.